The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Accelerating Medicines Partnership Targets Therapies for Rheumatoid Arthritis, Systemic Lupus Erythematosus

Accelerating Medicines Partnership Targets Therapies for Rheumatoid Arthritis, Systemic Lupus Erythematosus

October 1, 2014 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Collaboration should help identify targets for effective therapies more quickly.
Collaboration should help identify targets for effective therapies more quickly.

An innovative partnership forged by the National Institutes of Health, 10 pharmaceutical companies and several nonprofit organizations is expected to improve the chances that the right targets will be found for development of new drugs to treat rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Called the Accelerating Medicines Partnership (AMP), the alliance is using a model different from traditional drug development by funding collaborative efforts to find targets for effective therapeutics more quickly.

You Might Also Like
  • Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network
  • Update on Accelerating Medicines Partnership
  • Accelerating Medicines Partnership Advances Research for Autoimmune Diseases
Explore This Issue
October 2014
Also By This Author
  • 2014 ACR/ARHP Annual Meeting: Innate Immunity at the Core of Rheumatic Disease

The “science is ripe,” NIH Director Francis S. Collins, MD, PhD, said at a recent press conference. “We’ve come a long way in recent years in our understanding of disease. As a result of technological advances and genomics, proteomics, imaging and more, researchers have increasingly been able to identify fundamental changes in genes, proteins and other molecules that predispose to diseases whose causes have vexed us for all of history.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The AMP will focus on RA and SLE, as well as Alzheimer’s disease and type 2 diabetes, with the partners investing more than $230 million in the total project over the first three to five years. The budget for the RA/SLE portion is $41.6 million, with that amount split roughly 50/50 between the NIH and its partners in the pharmaceutical industry.

Chemical Pathways in RA & SLE

RA and SLE research will focus on genes, proteins, chemical pathways and networks involved at a single-cell level, according to the NIH. In addition to analyzing single cells and groups of cells involved in autoimmunity, the project will collect tissue samples from people with RA and SLE for molecular analysis, develop computational tools to integrate data types so that molecular pathways can be understood and make the data available to the broad research community for further analysis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Jennifer Bell, PhD, research director of the Lupus Research Institute (LRI), says she is hopeful that AMP will generate “big data” on human lupus that can speed up the validation of pathways and new targets for diagnostics and drug development. Dr. Bell says the LRI and the Alliance for Lupus Research (ALR) are represented on the steering committee of AMP’s lupus/RA program and will have input about the governance, management and direction of research.

The ALR and LRI bring the unique perspective of nonprofit organizations that have been “an engine for discovery in lupus and, most importantly, the voice of lupus patients,” she says.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Legislation & Advocacy, Professional Topics, Rheumatoid Arthritis, SLE (Lupus) Tagged With: Advocacy, drug, Holliman, Lupus, Research, Rheumatoid arthritis, Rheumatology Research Foundation, SLE, Systemic lupus erythematosus, therapyIssue: October 2014

You Might Also Like:
  • Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network
  • Update on Accelerating Medicines Partnership
  • Accelerating Medicines Partnership Advances Research for Autoimmune Diseases
  • Systemic Lupus Erythematosus

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.